SEDPARK1: Safety and Efficacy Study With the Non-ergot Dopamine-agonist Piribedil in Parkinson's Disease
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The aim of the non-interventional Post Marketing Study is to investigate the use of the
non-ergot dopamine agonist piribedil (trade name: CLARIUM) in mono- and combination therapy
in patients with Morbus Parkinson. Tolerability and course of the disease or change of
parkinsonian symptoms during stabilisation on, or change over from other dopamine agonists
will be documented under routine conditions. Piribedil should be prescribed according to its
marketing authorisation by the responsible neurologist.